An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.
Original Article: Adding Nivolumab to Standard First-Line Therapy Feasible in Advanced Head and Neck Cancer